留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

脂解模型在脂质给药系统体外评价中的应用研究进展

曾棋平,  张晶,  刘志宏,  宋洪涛

downloadPDF
文章导航 > 药学实践与服务  > 2014 >  32(2): 85-87
曾棋平, 张晶, 刘志宏, 宋洪涛. 脂解模型在脂质给药系统体外评价中的应用研究进展[J]. 药学实践与服务, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
引用本文: 曾棋平, 张晶, 刘志宏, 宋洪涛. 脂解模型在脂质给药系统体外评价中的应用研究进展[J]. 药学实践与服务, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
shu
ZENG Qiping, ZHANG Jing, LIU Zhihong, SONG Hongtao. In vitro evaluation of lipid drug delivery system by lipolysis model[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
Citation: ZENG Qiping, ZHANG Jing, LIU Zhihong, SONG Hongtao. In vitro evaluation of lipid drug delivery system by lipolysis model[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
shu

脂解模型在脂质给药系统体外评价中的应用研究进展

doi: 10.3969/j.issn.1006-0111.2014.02.002
  • 1.

    南京军区福州总医院药学科, 福建 福州 350025;福建医科大学药学院, 福建 福州 350108

  • 2.

    南京军区福州总医院药学科, 福建 福州 350025

基金项目: 福建省自然科学基金(2010J01218).

In vitro evaluation of lipid drug delivery system by lipolysis model

  • 1.

    Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, China;School of Pharmacy, Fujian Medical University, Fuzhou 350108, China

  • 2.

    Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025, China

  • 摘要: 目的 综述脂解模型的组成及其在脂质制剂体外评价的应用,为推动脂质制剂的发展提供参考。 方法 通过查阅近年来国内外相关文献,归纳、分析和总结。 结果 体外脂解模型能准确反映脂质制剂在人体内的性质,建立良好的体内外相关性。 结论 脂解模型用于筛选和评价脂质制剂具有良好的应用前景。
    Abstract: Objective To review the composition of lipolysis model and the application in the in vitro evaluation of lipid formulations, provide reference for promoting the development of lipid formulations. Methods Recent relevant literatures were analyzed and summarized. Results In vitro lipolysis model could accurately reflect the in vivo nature of lipid formulations, and a good correlation between in vivo and in vitro could be established. Conclusion There is a good prospect in using lipolysis model for screening and evaluation of lipid formulations.
  • [1] Stella VJ,Nti-Addae KW.Prodrug strategies to overcome poor water solubility[J]. Adv Drug Deliv Rev, 2007, 59(7):677-694.
    [2] Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system:the scientific basis for biowaiver extensions[J]. Pharm Res, 2002,19(7):921-925.
    [3] Giliyar C, Fikstad DT, Tyavanagimatt S. Challenges and opportunities in oral delivery of poorly water-soluble drugs[J]. Drug Deliv Technol,2006,6(1):57-63.
    [4] Hauss DJ. Oral lipid-based formulations[J]. Adv Drug Deliv Rev, 2007,59(7):667-676.
    [5] Colin WP. Formulation of poorly water-soluble drugs for oral administration:physicochemical and physiological issues and the lipid formulation classification system[J]. Eur J Pharm,2006, 29(3-4):278-287.
    [6] Pouton CW. Formulation of poorly water soluble drugs for oral administration:physicochemical issues and the lipid formulation classification system[J]. Eur J Pharm, 2006(29):278-287.
    [7] Hamberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs[J]. Adv Drug Deliv Rev, 1997, 25:103-108.
    [8] Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration:materials, methods and strategies[J]. Adv Drug Deliv Rev, 2008, 60:625-637.
    [9] Setbia S, Squillante E. Solid dispersion:revival with greater possibilities and application in oral drug delivery[J]. Crit Rev Ther Drug Carrier Syst, 2003,20(2-3):215-247.
    [10] 安富荣, 苏德森. 生物技术药物的脂质体给药系统研究进展[J]. 中国生化药物杂志, 2003, 24(4):207-209.
    [11] 张 宁, 王海学, 钱思源. 浅谈细胞毒类抗肿瘤药物脂质体制剂的研究思路[J]. 中国新药杂志, 2006,15(21):1805-1807.
    [12] Porter CJH, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid based delivery systems[J]. Adv Drug Deliv Rev, 2008, 60:673-691.
    [13] Zangenberg NH, Mullertz A, Kristensen HG, et al. A dynamic in virto lipolysis model.Ⅰ:controlling the rate of lipolysis by continuous addition of calcium[J]. Eur J Pharm, 2001, 14:115-122.
    [14] Kaukonen AM, Boyd BJ, Porter CJH, et al. Drug solubilization behavior during in vitro digestion of simple triglyceride lipid solution formulation[J]. Pharm Res, 2004,21:245-253.
    [15] Zangenberg NH, Mullertz A, Kristensen HG, et al. A dynamic in virto lipolysis model. Ⅱ:evaluation of the model[J].Eur J Pharm, 2001, 14:237-244.
    [16] Larsen A, Sassene P, Mullertz A. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems[J]. Int J Pharm, 2011, 417:245-255.
    [17] Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize of poorly water soluble drugs:correlation with in vivo data and the relationship to intra enterocyte processes in rats[J]. Pharm Res, 2006, 23(9):2165-2174.
    [18] Sek L, Porter CJH, Charman WN, et al. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products,by HPLC coupled with in situ densitometric analysis[J]. J Pharm Biomed Anal, 2001, 25(3-4):651-661.
    [19] Fatouros DG, Nielsen FS, Douroumis D, et al. In vitro-in vivo correlations of self emulsifying drug delivery systems combining the dynamic lipolysis model and neuro fuzzy networks[J]. Eur J Pharm, 2008, 69:887-898.
    [20] 宦 娣, 易 涛, 刘 颖, 等. 微粉硅胶对固体自微乳化给药系统小肠吸收的影响[J]. 药学学报, 2011, 46 (4):466-471.
    [21] 刘 颖, 肖 璐, 何吉奎, 等. 脂质制剂体外动态肠吸收模型的建立及评价[J]. 药学学报, 2011, 46(8):983-989.
    [22] 刘 颖, 易 涛, 宦 娣, 等. 利用体外脂解模型评价Ⅰ型脂质制剂[J]. 药学学报, 2010, 45 (10):1307-1311.
  • [1] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202306040
    [2] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [3] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202310044
    [4] 王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉.  全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
    [5] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2124
  • HTML全文浏览量:  190
  • PDF下载量:  254
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-04-25
  • 修回日期:  2013-11-04

脂解模型在脂质给药系统体外评价中的应用研究进展

doi: 10.3969/j.issn.1006-0111.2014.02.002
  • 1. 南京军区福州总医院药学科, 福建 福州 350025;福建医科大学药学院, 福建 福州 350108
  • 2. 南京军区福州总医院药学科, 福建 福州 350025
    • 基金项目:  福建省自然科学基金(2010J01218).
  • 收稿日期: 2013-04-25
  • 修回日期: 2013-11-04

摘要: 目的 综述脂解模型的组成及其在脂质制剂体外评价的应用,为推动脂质制剂的发展提供参考。 方法 通过查阅近年来国内外相关文献,归纳、分析和总结。 结果 体外脂解模型能准确反映脂质制剂在人体内的性质,建立良好的体内外相关性。 结论 脂解模型用于筛选和评价脂质制剂具有良好的应用前景。

English Abstract

曾棋平, 张晶, 刘志宏, 宋洪涛. 脂解模型在脂质给药系统体外评价中的应用研究进展[J]. 药学实践与服务, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
引用本文: 曾棋平, 张晶, 刘志宏, 宋洪涛. 脂解模型在脂质给药系统体外评价中的应用研究进展[J]. 药学实践与服务, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
shu
ZENG Qiping, ZHANG Jing, LIU Zhihong, SONG Hongtao. In vitro evaluation of lipid drug delivery system by lipolysis model[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
Citation: ZENG Qiping, ZHANG Jing, LIU Zhihong, SONG Hongtao. In vitro evaluation of lipid drug delivery system by lipolysis model[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(2): 85-87. doi: 10.3969/j.issn.1006-0111.2014.02.002
shu

    全文HTML

参考文献 (22)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计